BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9049779)

  • 1. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
    J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
    J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
    Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
    Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
    J Biol Regul Homeost Agents; 1994; 8(4):126-9. PubMed ID: 7660855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
    Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
    Lissoni P
    Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
    Lissoni P
    Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
    Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.
    ViganĂ² D; Lissoni P; Rovelli F; Roselli MG; Malugani F; Gavazzeni C; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2001 Apr; 22(2):137-41. PubMed ID: 11335890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for melatonin in supportive care?
    Lissoni P
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pineal gland as a central regulator of cytokine network.
    Lissoni P
    Neuro Endocrinol Lett; 1999; 20(6):343-349. PubMed ID: 11458197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans.
    Lissoni P; Rovelli F; Brivio F; Brivio O; Fumagalli L
    Nat Immun; 1998; 16(1):1-5. PubMed ID: 9789119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
    Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
    In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin as biological response modifier in cancer patients.
    Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
    Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
    Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
    J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
    Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.